• OncoMethylome Sciences SA, of Durham, N.C., appointed Melissa A. Thompson vice president of regulatory affairs and quality assurance and named Christopher (Chris) Thibodeau vice president of commercial operations.

• Oncothyreon Inc., of Seattle, appointed Julie M. Eastland chief financial officer and vice president of corporate development.

• Pepscan Therapeutics BV, of Lelystad, the Netherlands, named Andrew Hamilton, Andreas Pluckthun and Reinhold Foerster to its scientific advisory board chaired by Gregory Winter.

• Phosphagenics Ltd., of Melbourne, Australia, appointed Stuart James, Sandra Webb and Don Clarke nonexecutive directors.

• Portola Pharmaceuticals Inc., of South San Francisco, appointed Jean-Jacques Bienaime to its board.

• Predictive Biosciences Inc., of Lexington, Mass., appointed Thomas M. Ross chief commercial officer and named Randal Vader vice president of clinical and regulatory affairs.

• Probiodrug AG, of Halle, Germany, appointed Kumar Srinivasan chief business officer.

• Prolong Pharmaceuticals Inc., of South Plainfield, N.J., named Glenn Kazo president.

• Protalix BioTherapeutics Inc., of Carmiel, Israel, appointed Tzvi Palash chief operating officer.

• RegeneRx Biopharmaceuticals Inc., of Rockville, Md., appointed R. Don Elsey to its board.

• Regenicin Inc., of New York, added Joseph Rubinfeld and Craig Eagle to its board.

• Rexahn Pharmaceuticals Inc., of Rockville, Md., appointed Peter Brandt and Richard Kivel to its board.

• Ricerca Biosciences LLC, of Concord, Ohio, added Lawrence (Bob) Lima III as director of analytical chemistry.

• Saladax Biomedical Inc., of Bethlehem, Pa., added Gregory Critchfield to its board.

• Scolr Pharma Inc., of Bothell, Wash., appointed Carl Johnson chairman.

• Senomyx Inc., of San Diego, added Mary Ann Gray to its board.

• Sernova Corp., of London, Ontario, appointed James Shapiro to its scientific advisory board.

• Sofinnova Ventures, of Menlo Park, Calif., added Garheng Kong as general partner.

• Somaxon Pharmaceuticals Inc., of San Diego, named Faheem Hasnain an independent director.

• Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, added Paul Brennan senior vice president of business development.

• Unigene Laboratories Inc., of Boonton, N.J., elected Joel A. Tune to its board.

• Vermillion Inc., of Austin, Texas, named Jeffrey M. Salzman corporate director of reimbursement.

• Vaccinogen Inc., of Frderick, Md., has appointed veteran biotechnology executive Michael L. Kranda president and CEO

• XOMA Ltd., of Berkeley, Calif., elected Jack L. Wyszomierski to its board.